Clinical Trial Update: CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating CBX-12 for metastatic colorectal cancer that is mismatch repair proficient has been withdrawn, with no ongoing enrollment or results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CBX-12

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma | Phase 2 | Status: WITHDRAWN